The Group continuously launches “three-high” products (high-tech, high-quality, high value-added). It owns 309 production licenses for drugs, 6 production licenses for sterilization products and 48 certificates of new drugs. 13 scientific research projects are included in the national, provincial and municipal key construction projects, special self-innovation plan, and have also received science and technology awards. 8 products are included in National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Twelfth Five-year Plan Period, 12 products in China Torch Plan and 4 products in National New Products Program. 110 products are applying for China's invention patent while 151 products have been granted with China's invention patent. The Group has been honored as “Optimal Industrial Enterprise on the Pharmaceutical Product R&D Line of China” for consecutive years. Innovation in science and technology brings about innovation of products. The abundant national new drugs developed have filled the void in China.
In order to pace up the scientific research and innovation and achieve a virtuous circulation of “one-generation production, one-generation reserve, one-generation research”, the Group increases investment in science and technology year by year, and also invests heavily in equipment & facility, talent team construction, research and development of innovative drugs, to guarantee constant harvest of innovative outcomes.
<i id='d116c'><strike id='7e0d3'><tt id='c191a'><pre id='8788b'></pre></tt></strike></i>